Electronic Health Record Alert on PSA Screening Rates
Annual PSA Health Maintenance Reminder
Urogenital Diseases+7
+ Genital Diseases
+ Genital Diseases, Male
Services Research Study
Summary
Study start date: August 11, 2025
Actual date on which the first participant was enrolled.This clinical trial aims to examine how using electronic health record alerts can influence the rates of PSA screening, a test for prostate cancer, across a network of ten hospitals. The focus is on encouraging annual discussions between healthcare providers and patients about PSA screening, using technology to support decisions based on the latest guidelines for prostate cancer risk. This study is important because it seeks to catch prostate cancer early while reducing unnecessary diagnoses, thereby improving patient care by ensuring that screenings are both available and effective. Participants in the study will engage in shared decision-making conversations guided by enhanced clinical decision support tools. These tools help standardize how healthcare providers decide on and refer patients for PSA screening, based on clinical guidelines. The study evaluates the effectiveness of these tools in reducing differences in how providers screen for prostate cancer and in ensuring that the screenings align with recommended practices. By doing so, the study hopes to find a balance between catching cancer early and avoiding unneeded treatments.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.40000 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Services Research Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Male
Biological sex of participants that are eligible to enroll.From 40 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Eligibility Criteria: * Receive care within the BJC Health System * Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care) * Be male * Not have a history of prostate cancer * Meet one of the following risk criteria: * High Risk for Prostate Cancer * African American, between the ages of 40 and 75 (inclusive), or * Family history of prostate, breast, ovarian, and/or pancreatic cancer, or * Known familial germline mutation OR * Average Risk for Prostate Cancer * Between the ages of 50 and 75 (inclusive)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location